From 1 July 2023, Vaxelis® has been added to the National Immunisation Program (NIP) schedule.
Vaxelis® is a hexavalent (six-in-one) vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type B (Hib). Vaxelis® is an alternative to Infanrix® hexa, for primary vaccination at 6 weeks, 4 months and 6 months. It can also be used for catch-up vaccination in children under 10 years of age. There is no preferred vaccine between the two options and both have a similar safety profile.
Vaxelis® is a single-dose 0.5 mL pre-filled syringe and, unlike Infanrix® hexa, does not require reconstitution. Vaxelis® has a whiteish, cloudy appearance.
Completing a primary course of vaccination with the same brand of hexavalent vaccine is preferred. However, where this is not possible the alternate brand may be used.
Vaxelis® can be given on the same day as other vaccines and can be administered in the same limb as other vaccines. Where more than one vaccine is administered into the same limb, a spacing of 2.5 cm should be maintained.